Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGV002 mRNA Vaccine in Advanced Gastric, Esophageal, and Liver Cancer
NCT05192460Phase 1Unknown
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV002 in gastric cancer (GC), esophageal cancer and liver cancer. Primary endpoints: Incidence and degree of Adverse Events and Serious Adverse Events up to 100 weeks and Objective Response Rate up to 100 weeks. Status: unknown.
02
Drugs
PGV002
03
Conditions
gastric cancer (GC)esophageal cancerliver cancer
Beyond the preview
Go deeper on NCT05192460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192460.